Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:2009:bcr11.2008.1257.
doi: 10.1136/bcr.11.2008.1257. Epub 2009 Aug 10.

Dapsone hypersensitivity syndrome causing disseminated intravascular coagulation

Affiliations

Dapsone hypersensitivity syndrome causing disseminated intravascular coagulation

Melanie Clare Figtree et al. BMJ Case Rep. 2009.

Abstract

Dapsone hypersensitivity syndrome is an idiosyncratic reaction to this drug and can present with different clinical manifestations of varying severity. We describe a patient with disseminated intravascular coagulation (DIC) as an adverse reaction to dapsone. To the best of our knowledge, this is the first time it has been described in the literature. She presented with fever, rash and abdominal pain; she also had marked eosinophilia and features suggestive of oxidative haemolysis. Her course was complicated by DIC, splenic infarction and gastrointestinal bleeding. Extensive investigations did not reveal any alternative aetiology. She was initially treated with supportive measures and folic acid; steroids were administered later, following clinical deterioration. There was gradual improvement and the steroids were tapered. The patient recovered fully and remains well; her underlying chronic dermatologic condition is under satisfactory control with other medications.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Exanthem of dapsone hypersensitivity reaction on abdomen. (B) Peripheral blood film showing oxidative haemolysis. (C) Computed tomographic scan of the abdomen showing splenic infarction, bilateral pleural effusions and body wall oedema.

References

    1. Kosseifi SG, Guha B, Nassour DN, et al. The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. J Occup Med Toxicol 2006;1:9. - PMC - PubMed
    1. Richardus JH, Smith TC. Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Lepr Rev 1989;60:267–73 - PubMed
    1. Pandey B, Shrestha K, Lewis J, et al. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal. Trop Doct 2007;37:162–3 - PubMed
    1. Bluhm RE, Adedoyin A, McCarver DG, et al. Development of dapsone toxicity in patients with inflammatory dermatosis: activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Ther 1999;65:598–605 - PubMed
    1. Gando S, Iba T, Eguchi Y, et al. A multicentre, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006;34:625–31 - PubMed

LinkOut - more resources